Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Guilhot

Showing results (151-160 of 154) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 154 results.
The New England Journal of Medicine|November 5, 2013
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasJ E Cortes, D-W Kim, J Pinilla-Ibarz, et al.
Leukemia|March 5, 2020
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemiaA Hochhaus, M Baccarani, R T Silver, et al.
Leukemia|October 27, 2015
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletionA Toma, O Kosmider, S Chevret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2011
No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patientsU Thiel, A Wawer, P Wolf, et al.
Pageof 16

Showing results (151-160 of 154) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 154 results.
The New England Journal of Medicine|November 5, 2013
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasJ E Cortes, D-W Kim, J Pinilla-Ibarz, et al.
Leukemia|March 5, 2020
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemiaA Hochhaus, M Baccarani, R T Silver, et al.
Leukemia|October 27, 2015
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletionA Toma, O Kosmider, S Chevret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2011
No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patientsU Thiel, A Wawer, P Wolf, et al.
Pageof 16